Immunomedics drug impresses with new data
Well, now we know why Gilead Sciences ponied up the $21 billion to acquire Immunomedics this month. Clinical data on the company’s cancer drug, Trodelvy, were released over the weekend at ESMO and were clearly promising, STAT’s Adam Feuerstein writes. The results exceeded expectations, and suggest the Immunomedics therapy could grow into a multibillion-dollar drug.
Trodelvy, which was approved in April for triple-negative breast cancer, showed an overall tumor response rate of 27% in metastatic bladder cancer — among volunteers who had failed both chemotherapy and immunotherapy. On top of that, 5% of trial participants saw remission. Patients in the study showed progression-free survival of 5.4 months.
Even more indicative of the drug’s potential commercial success: Trodelvy reduced the risk of death by 52% in patients with triple-negative breast cancer compared to chemotherapy.
Trodelvy, which was approved in April for triple-negative breast cancer, showed an overall tumor response rate of 27% in metastatic bladder cancer — among volunteers who had failed both chemotherapy and immunotherapy. On top of that, 5% of trial participants saw remission. Patients in the study showed progression-free survival of 5.4 months.
Even more indicative of the drug’s potential commercial success: Trodelvy reduced the risk of death by 52% in patients with triple-negative breast cancer compared to chemotherapy.
.png)
No hay comentarios:
Publicar un comentario